SMMT Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of -- compared to Summit Therapeutics's net margin of -227.46%. Summit Therapeutics's return on equity of -- beat BioNTech SE's return on equity of -3.91%.

Summit Therapeutics has a consensus price target of $37.47, signalling upside risk potential of 82%. On the other hand BioNTech SE has an analysts' consensus of $133.08 which suggests that it could grow by 22.66%. Given that Summit Therapeutics has higher upside potential than BioNTech SE, analysts believe Summit Therapeutics is more attractive than BioNTech SE.

Summit Therapeutics has a beta of -1.058, which suggesting that the stock is 205.802% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.759%.

Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.

Summit Therapeutics quarterly revenues are --, which are smaller than BioNTech SE quarterly revenues of $192.3M. Summit Therapeutics's net income of -$62.9M is higher than BioNTech SE's net income of -$437.5M. Notably, Summit Therapeutics's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 15,670.26x versus 8.79x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -- compared to Summit Therapeutics's net margin of 32.71%. Summit Therapeutics's return on equity of -- beat Merck &'s return on equity of 39.02%.

Summit Therapeutics has a consensus price target of $37.47, signalling upside risk potential of 82%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 28.89%. Given that Summit Therapeutics has higher upside potential than Merck &, analysts believe Summit Therapeutics is more attractive than Merck &.

Summit Therapeutics has a beta of -1.058, which suggesting that the stock is 205.802% less volatile than S&P 500. In comparison Merck & has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.863%.

Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4% to investors and pays a quarterly dividend of $0.81 per share. Summit Therapeutics pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Summit Therapeutics quarterly revenues are --, which are smaller than Merck & quarterly revenues of $15.5B. Summit Therapeutics's net income of -$62.9M is lower than Merck &'s net income of $5.1B. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Merck &'s PE ratio is 11.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 15,670.26x versus 3.14x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Summit Therapeutics's net margin of 21.63%. Summit Therapeutics's return on equity of -- beat Pfizer's return on equity of 8.72%.

Summit Therapeutics has a consensus price target of $37.47, signalling upside risk potential of 82%. On the other hand Pfizer has an analysts' consensus of $29.24 which suggests that it could grow by 25.22%. Given that Summit Therapeutics has higher upside potential than Pfizer, analysts believe Summit Therapeutics is more attractive than Pfizer.

Summit Therapeutics has a beta of -1.058, which suggesting that the stock is 205.802% less volatile than S&P 500. In comparison Pfizer has a beta of 0.572, suggesting its less volatile than the S&P 500 by 42.759%.

Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.28% to investors and pays a quarterly dividend of $0.43 per share. Summit Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Summit Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $13.7B. Summit Therapeutics's net income of -$62.9M is lower than Pfizer's net income of $3B. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 16.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 15,670.26x versus 2.13x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Instil Bio has a net margin of -- compared to Summit Therapeutics's net margin of --. Summit Therapeutics's return on equity of -- beat Instil Bio's return on equity of --.

Summit Therapeutics has a consensus price target of $37.47, signalling upside risk potential of 82%. On the other hand Instil Bio has an analysts' consensus of $118.67 which suggests that it could grow by 244.96%. Given that Instil Bio has higher upside potential than Summit Therapeutics, analysts believe Instil Bio is more attractive than Summit Therapeutics.

Summit Therapeutics has a beta of -1.058, which suggesting that the stock is 205.802% less volatile than S&P 500. In comparison Instil Bio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Instil Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics pays -- of its earnings as a dividend. Instil Bio pays out -- of its earnings as a dividend.

Summit Therapeutics quarterly revenues are --, which are smaller than Instil Bio quarterly revenues of --. Summit Therapeutics's net income of -$62.9M is lower than Instil Bio's net income of -$28.2M. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Instil Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 15,670.26x versus -- for Instil Bio. Usually stocks with elevated PS ratios are considered overvalued.